The proposed conference is the ninth conference devoted to monoclonal antibody conjugates for clinical use in cancer. Leading researchers from around the world present latest results of their clinical trials in man, as well as pre-clinical studies using monoclonal antibodies linked to isotopes, drugs, and toxins for cancer therapy and detection. The program will consist of 5 half-day sessions over a 2 1/2 day period. The sessions will include both invited speakers and the presentation of proffered abstracts describing recent clinical and pre-clinical data. This conference is of interest to tumor immunologists, biotechnologists, medical oncologists, radiation therapists, nuclear medicine immunologists, nuclear medicine physicians and other interested health professionals and researchers working in this field, and brings together investigators and clinicians from academia, industry and government.
